Melt Pharmaceuticals, Inc.

About Melt Pharmaceuticals, Inc.

Melt Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company dedicated to developing and commercializing patented non-intravenous and non-opioid sedation and analgesia medicines for short-duration medical procedures in outpatient and in-office settings. Their mission is to revolutionize the surgical patient experience with innovative drug formulations.

Products & Services

MELT-300:A lead product candidate, MELT-300 is a rapidly dissolving sublingual tablet designed for needle- and opioid-free procedural sedation and analgesia, specifically for patients undergoing cataract surgery.

Combination Non-Opioid Sedation Drugs:A series of patented drug formulations aimed at replacing or supplementing current sedation modalities for over 100 million medical procedures in the United States.

Specialties

Non-intravenous sedation Non-opioid analgesia Procedural sedation for short-duration medical procedures Sublingual drug delivery

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series B T: - FT: Series B	A: 24000000 MR: - FA: approximately $24 million FAN: 24000000	D: 2024-04-02 FD: 2024-04-02	-

Series B Latest

2024-04-02

$24.0M

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

L

Larry Dillaha

Chief Executive Officer

M

Mark L. Baum

Director

J

John Berdahl

MD

J

J. Andy Corley

Director

A

Arthur Laffer

Director

B

Brad Osborne

Chief Financial Officer

View 4 more team members with Pro

Unlock Full Team Directory

Recent News